Literature DB >> 15718253

22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer.

Kimie Nakagawa1, Yuko Sasaki, Shigeaki Kato, Noboru Kubodera, Toshio Okano.   

Abstract

1alpha,25-Dihydroxyvitamin D(3) (1alpha,25-D(3)) has potent antiproliferative and anti-invasive properties in vitro in cancer cells. However, its calcemic effect in vivo limits its therapeutic applications. Here, we report the efficacy of 22-oxa-1alpha,25-dihydroxyvitamin D(3) (22-oxa-1alpha,25-D(3)), a low calcemic analog of vitamin D, against the development of metastatic lung carcinoma after an intravenous injection of green fluorescent protein-transfected Lewis lung carcinoma (LLC-GFP) cells in C57BL/6 mice. The mice injected with tumor cells were implanted simultaneously with osmotic minipumps containing either 1alpha,25-D(3), 22-oxa-1alpha,25-D(3) or vehicle. The 1alpha,25-D(3) treatment group had been hypercalcemic, but the 22-oxa-1alpha,25-D(3) and vehicle treatment groups remained normocalcemic for the duration of the experiment. The total number of lung metastases, lung weight and the expression of GFP mRNA in the lung were markedly decreased in 1alpha,25-D(3) and 22-oxa-1alpha,25-D(3)-treated mice. In the in vitro experiment, 1alpha,25-D(3) and 22-oxa-1alpha,25-D(3) reduced the expression of matrix metalloproteinase (MMP)-2, MMP-9, vascular endothelial growth factor and parathyroid hormone-related protein in LLC-GFP cells. Furthermore, in the angiogenesis assay, the number of tumor cells or basic fibroblast growth factor-induced angiogenesis was reduced in 1alpha,25-D(3) and 22-oxa-1alpha,25-D(3)-treated mice. Moreover, using a new experimental model of vitamin D receptor (VDR) null mutant (VDR(-/-)) mice with corrected hypocalcemia and hypervitaminosis D, we examine the anti-cancer effect of 22-oxa-1alpha,25-D(3) without other functions induced by 22-oxa-1alpha,25-D(3) in the host. In the VDR(-/-) mice, 22-oxa-1alpha,25-D(3) directly inhibited the metastatic activity of LLC-GFP cells in a dose-dependent manner without exerting a direct influence on the calcemic activity or other actions regulated by 22-oxa-1alpha,25-D(3) in the host. These results indicate that the inhibition of metastasis and angiogenesis-inducing activity in cancer cells seemed to be a major mechanism responsible for the anti-cancer effects of 22-oxa-1alpha,25-D(3). Our findings show that 22-oxa-1alpha,25-D(3) is beneficial for the prevention of metastasis in lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718253     DOI: 10.1093/carcin/bgi049

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  42 in total

Review 1.  The role of vitamin D in hepatic metastases from colorectal cancer.

Authors:  E Shaw; N Massaro; N T Brockton
Journal:  Clin Transl Oncol       Date:  2017-08-11       Impact factor: 3.405

Review 2.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

3.  Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis.

Authors:  Yonghua Xu; Xiaoping Shao; Yacheng Yao; Lijian Xu; Liang Chang; Zhuojuan Jiang; Zhaofen Lin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-17       Impact factor: 4.553

4.  Serum vitamin D, vitamin D binding protein, and lung cancer survival.

Authors:  Gabriella M Anic; Stephanie J Weinstein; Alison M Mondul; Satu Männistö; Demetrius Albanes
Journal:  Lung Cancer       Date:  2014-10-20       Impact factor: 5.705

5.  Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity.

Authors:  Andrzej T Slominski; Zorica Janjetovic; Brian E Fuller; Michal A Zmijewski; Robert C Tuckey; Minh N Nguyen; Trevor Sweatman; Wei Li; Jordan Zjawiony; Duane Miller; Tai C Chen; Gerard Lozanski; Michael F Holick
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

6.  Association of vitamin D receptor FokI and ApaI polymorphisms with lung cancer risk in Tunisian population.

Authors:  Wajih Kaabachi; Safa Kaabachi; Ahlem Rafrafi; Amira Ben Amor; Kalthoum Tizaoui; Faycal Haj Sassi; Kamel Hamzaoui
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

Review 7.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

Review 8.  Vitamin D and human health: lessons from vitamin D receptor null mice.

Authors:  Roger Bouillon; Geert Carmeliet; Lieve Verlinden; Evelyne van Etten; Annemieke Verstuyf; Hilary F Luderer; Liesbet Lieben; Chantal Mathieu; Marie Demay
Journal:  Endocr Rev       Date:  2008-08-11       Impact factor: 19.871

9.  Antimetastatic activity of MONCPT in preclinical melanoma mice model.

Authors:  Xiao-Chun Yang; Chong-Xing Tu; Pei-Hua Luo; Hong Zhu; Di-Feng Zhu; Hong-Hai Wu; Xing-Lu Zhou; Wei Lu; Qiao-Jun He; Bo Yang
Journal:  Invest New Drugs       Date:  2009-09-30       Impact factor: 3.850

10.  Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol.

Authors:  Yingyu Ma; Wei-Dong Yu; Bing Su; Mukund Seshadri; Wei Luo; Donald L Trump; Candace S Johnson
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.